CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 328 enrolled
Drug / intervention
OMEGA™ Monorail Coronary Stent Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01419171
NCT01419171N/ACompleted

OMEGA: A Prospective, Multicenter Single-Arm Trial to Assess the OMEGA™ Coronary Stent System for the Treatment of a Single De Novo Coronary Artery Lesion

Boston Scientific Corporation·interventional·Posted Aug 18, 2011·Updated Sep 25, 2014

In Brief

A clinical study evaluating OMEGA™ Monorail Coronary Stent System for Atherosclerosis and Coronary Artery Disease. Completed, enrolled 328 participants across 37 sites in 7 countries.

Detailed Summary

The purpose of this study is to evaluate the safety and effectiveness of the OMEGA Coronary Stent System for the treatment of subjects with a de novo atherosclerotic coronary artery lesion.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, France, Germany, Latvia, Netherlands, Spain, United States
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 18, 2011
Enrollment StartOct 1, 2011
Primary CompletionOct 1, 2013
Study CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 14.9 years ago

Interventions

OMEGA™ Monorail Coronary Stent Systemdevice

All enrolled patients are treated with the OMEGA™ Monorail Bare Metal Coronary Stent System and followed for 12 months post-procedure.